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A B S T R A C T
Background: Standard approaches to estimation of Markov models with data from random-
ized controlled trials tend either to make a judgment about which transition(s) treatments act
on, or they assume that treatment has a separate effect on every transition. An alternative is to
fit a series of models that assume that treatment acts on specific transitions. Investigators can
then choose among alternative models using goodness-of-fit statistics. However, structural
uncertainty about any chosenparameterizationwill remain and thismayhave implications for
the resulting decision and the need for further research.
Methods: Wedescribe a Bayesian approach tomodel estimation, andmodel selection. Struc-
tural uncertainty about which parameterization to use is accounted for usingmodel averaging
andwe developed a formula for calculating the expected value of perfect information (EVPI) in
averagedmodels. Marginal posterior distributions are generated for each of the cost-effective-
ness parameters using Markov Chain Monte Carlo simulation in WinBUGS, or Monte-Carlo
simulation in Excel (Microsoft Corp., Redmond,WA).We illustrate the approachwith an exam-
ple of treatments for asthma using aggregate-level data from a connected network of four
treatments compared in three pair-wise randomized controlled trials.
Results: The standard errors of incremental net benefit using structuredmodels is reduced by
up to eight- or ninefold compared to the unstructuredmodels, and the expected loss attaching
to decision uncertainty by factors of several hundreds. Model averaging had considerable in-
fluence on the EVPI.
Conclusions: Alternative structural assumptions can alter the treatment decision and have an
overwhelming effect on model uncertainty and expected value of information. Structural uncer-
taintycanbeaccountedforbymodelaveraging,andtheEVPIcanbecalculatedforaveragedmodels.
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Perhaps the most common approach to estimating Markov
models in health economic evaluations is to use a cohort
study to inform an underlying transition probability model
with a series of intermediate and absorbing states, and then
use randomized controlled trials (RCTs) [1–3] or meta-analy-
ses of RCTs [4–6] to inform the treatment effects. However,
the end points reported in the trials are seldom as specific as
the states in an economic model and it is unlikely that infor-
mation for all transitions in the model will be available in
more than a small proportion, if any, of the relevant trials. As
a result, in the absence of data, analysts have tomake a choice
about which transitions the treatment effect applies to, and
on occasions this may be somewhat arbitrary.
The most straightforward way to estimate a treatment ef-
fect from randomized trial data in the context of a Markov
transition probability model is to fit a separate model to each
arm [7]. We refer to this as an unstructured model, or as a
completely saturated parameterization, because there are ef-
fectively as many treatment effect parameters as there are
transitions in the model. Although this method is conceptu-
ally simple it has twomajor disadvantages. First, inference is
weakened as the treatment effect is heavily overparameter-
ized, and it is not reasonable to believe that treatment ef-
fects on different transitions are all entirely independent.
Second, it is very difficult to generalize the treatment effect
outside of the study, nor can the results of several trials be
synthesized.
Price et al. [8,9] have recently proposed an alternative ap-
proach, which in common with [7] estimates the transition
parameters jointly, but additionally allows for synthesis of
evidence from several trials, and facilitates generalizability of
results and calibration to other cohorts [10]. The critical fea-
ture of thismethod is that theMarkovmodel is parameterized
in terms of rates, rather than transition probabilities, which
allows for a flexible, structured representation of the mecha-
nism of action of the treatments in terms of which transitions
they act on. Alternative models, each representing a clinical
hypothesis about the mode of action of a treatment, can then
be explored and compared on the basis of statistical goodness-
of-fit criteria. This bases the choice of parameterization on the
empirical evidence. Working within a Bayesian Markov Chain
Monte Carlo (MCMC) framework, Price et al. [8,9] select a treat-
ment parameterization on the basis of a trade-off between
the fit and complexity of the model, using the deviance in-
formation criterion (DIC) [11], an analogue to the Akaike
information criterion (AIC) [12] used for model selection in
classical statistics.
Even if a preferred model can be reasonably selected, the
uncertainty in its outputs will underestimate the true uncer-
tainty in a decision context. This is because the outputs of a
decision model such as the marginal posterior distributions
for the optimal treatment decisions, decision uncertainty, and
the expected value of information [13–15] are all conditioned
on the statistical model used to estimate the transition pa-
rameters [16]. Hence, there is the implicit assumption that, of
those models considered, the one that is most likely to be
correct, is correct. Sensitivity of the results to the parameter-ization may be examined but this still does not provide a de-
finitive solution to the underlying problem of structural, or
model, uncertainty. One method for taking account of this
structural uncertainty in the analysis is through the use of
Bayesian model averaging [12,16–20]. Methods for model av-
eraging arewell established but their use in cost-effectiveness
analysis of health interventions has been limited. A recent
review by Bojke et al. [19] examined 13 UK National Institute
for Health Research Health Technology Assessment reports
and found that none of them used model averaging and as-
sessment of structural uncertainty was limited to running dif-
ferent scenarios. Bojke et al. [19] investigated the use ofmodel
averaging and its effect on the treatment decision and value of
information, but assumed equal weights for each of the can-
didate models. Subsequently Jackson et al. [21,22] applied
Bayesian model averaging to economic models.
The purpose of the research presented in this article was to
investigate the effect of model parameterization and model
uncertainty on the expected value of perfect information
(EVPI). We illustrate this in the context of aMarkovmodel that
has uncertainty over how the treatment effect is parameter-
ized. We show how EVPI analysis can be applied to averaged
models, and compare the treatment decision and EVPI esti-
mated by each candidate treatment model with estimates
from an averaged model. We use as an example aggregate-
level data from a connected network of four treatments for
asthma compared in three pair-wise RCTsA versus B, A versus
C, and A versus D. Five different parameterizations for mod-
elling the treatment effects are considered. We use the ex-
pected net monetary benefit as the basis for treatment deci-
sions and the EVPI as a measure of the expected loss arising
frommaking a decision based on current, imperfect, evidence
[23,24]. A formula for estimating the EVPI in the presence of
structural uncertainty is developed. Evidence synthesis and
estimation are integrated within cost-effectiveness analysis
and posterior summaries for the decision outputs, including
the net benefit and EVPI are obtained.
Section two describes the data, the alternative treatment
models being compared, model averaging, the economic
model, and the methodology for calculating the relevant
cost-effectiveness analysis and EVPI outputs, including the
introduction of a formula for estimating the EVPI using an
averaged model. Section three presents the results of the
cost-effectiveness analysis and the EVPI calculations gener-
ated using eachmodel. Results are presented for an analysis
using a mixed treatment comparison meta-analysis [25–27].
Finally, the findings and implications are discussed in more
detail.
Methods
Data
A cost-effectiveness analysis is performedusing example data
from three independent two-arm RCTs comparing treatments
A versus B, A versus C, and A versus D, respectively, for
asthma. Data from two further trials comparing treatments E
versus F, and G versus H, which are external to the decision
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207V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8space, are used to inform the model selection process. All tri-
als report data in the same format and the available data from
the A versus D trial are shown as an example in Table 1. Sub-
jects were followed-up for 12 weeks and in each week are
recorded as being in one of four possible mutually exclusive
and exhaustive clinically defined health states: Successfully
TreatedWeek (STW), Unsuccessfully TreatedWeek, Exacerba-
tion, or Treatment Failure (TF). In a single week, transitions
are possible from any state, except TF, to any of the four pos-
sible states (Fig. 1A). The data are reported in the form of
counts of the transitions between different states in consecu-
tive weeks, aggregated over all individuals, and over time.
This is the only form inwhich the data are available for each of
the trials and provides interval-censored observations on the
state transitions that may take place at any time within each
weekly cycle.
Parameterization of treatment effects
We fit a homogenous Markov model; this assumes that the
transition parameters are independent of time, and depend
only on observed cycle length (elapsed time). Because the data
are in aggregate form it is also necessary to assume homoge-
neity of the transition parameters across subjects [8]. Let pm-
kij(t) denote the probability of making a transition from state i
o state j over an observed time period t (in weeks), for treat-
ment k in study m, where:
i, j 1, 2, 3, 4 : 1 STW, 2UTW, 3X, 4TF.
The data are in aggregate form ymkij, which represents
he total number of observed transitions from state i to state
in any 1-week period, for treatment k in study m. The data
re observed over 1-week cycles, and therefore provide di-
ect information on pmkij(1). The cell counts for all transi-
tions from state i, are assumed to have a multinomial like-
lihood:
ymki1, ymki2, ymki3, ymki4
Table 1 – Data for the A vs. D trial. The numbers
represent the total counts of 1-week transitions from
each state, summed over all individuals over the entire
duration of the study.
State at t  1
STW UTW X TF
Treatment A STW 310 70 2 0
State at time t UTW 96 1683 11 13
X 1 11 1 0
TF 0 0 0 94
Treatment D STW 241 63 0 0
State at time t UTW 100 1777 12 11
X 0 10 3 3
TF 0 0 0 118
STW, Successfully Treated Week; UTW, Unsuccessfully Treated
Week; X, Exacerbation; TF, Treatment Failure.Multinomialpmki11, pmki21, pmki31, pmki41; nmkisubject to:

j1
4
pmkij1 1, 0 pmkij1 1, 
j1
4
ymkijnmki.
The transition probabilities may be modelled directly us-
ng, for example, polychotomous logistic regression [28,29].
owever, by modelling the transition rates using log-linear
egression, treatment effects are specified as hazard ratios,
hich are transportable across trials, rather than relative risks
hat depend on Markov cycle length. This approach also facil-
tates handling data in which some transitions may be unob-
erved [10]. Finally, it is possible that some transitions (e.g.
–3) may arise only via an intermediate state (1–2–3). A prob-
bility model requires three parameters (1–2, 1–3, 2–3)
hereas a rate model may provide a more realistic represen-
ation of the disease process requiring only two parameters
1–2, 2–3) to explain the same observed data. Rate models
herefore may lead to simpler, more intuitive, models with
ewer parameters [8,9], such as the six-transition model de-
cribed below, which cannot be fit using a discrete time for-
ulation. Further justification for the use of a continuous time
odel for this dataset is given in Price et al. [8]. The transition
robabilities from themultinomial likelihood are functionally
elated to the transition rates using Kolmogorov’s forward
quations [30,31]:
d
dt
Pmkt Pmkt .Gmk
where the transition probabilitymatrix Pm,k(t) has elements pmkij(t),
nd the transition ratematrixGmk has elements mkij.
Using this relationship it is possible to parameterize struc-
tured treatment models using transition rates and convert
these rates to transition probabilities to conform to the multi-
nomial likelihood for the data. In this way the Markov transi-
tion parametersmay be conceptualized as being functions of a
baseline progressionmodel and a further set of modifying pa-
rameters representing the effects of the different treatments.
Because the data are being modeled in continuous time, it is
unnecessary to model all nine of the possible transitions and
by comparing the DIC scores obtained by fitting models with
different numbers of parameters Price et al. [8,9] show that the
ain features of this data can be modeled with a six-transi-
ion parameter model [see 8–10 for further details of themod-
ling approach]. We assume that there are no structural rela-
ionships between the baseline transition rates mij. We fit the
following models to the treatment parameters kij (Fig. 1):
1. Saturated nine-parameter (SAT9)model—a completely sat-
urated rate parameterization (Fig. 1A) is fitted with an in-
dependent treatment parameter included for every possi-
ble transition.
2. Saturated six-parameter (SAT6) model—includes an inde-
pendent treatment parameter for every transition in the
reduced six-transition model (Fig. 1B).
3. Health improvement (HI) model—the treatment effect is
modelled with a single treatment parameter acting on all
backward transitions (Fig. 1C).
4. Maintenance and improvement (M&I)model—includes one
treatment effect parameter acting on all backward transi-
m
E
208 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8Fig. 1 – Transition diagrams and log-linear regression models for the rate parameters for the six treatment structures. The
transition rates mkij from state i to state j for persons on treatment k in study m are modeled with a log-linear relationship
to parameters representing the baseline progression rates mij and the relative treatment effects kij, which are given
inimally informative prior distributions. STW, Successfully Treated Week. UTW, Unsuccessfully Treated Week. X,
xacerbation. TF, Treatment Failure.
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STW state (Fig. 1D).
. Improvement and prevention (I&P) model—this model also
includes two treatment parameters. It allows the effect of
treatment to act on all of the backward transitions and in-
cludes second parameter acting on all of the forward tran-
sitions (Fig. 1E).
. Improvement, prevention, and longevity (I,P&L) model—this
model includes three treatment parameters. It allows the dif-
ference between the effects of the treatments to indepen-
dently affect the transitions to improved health states, the
transitions to the TF state, and the remainder of the transi-
tions to worse states of health (Fig. 1F).
7. Averagedmodel—estimation of the parameters and decision
outputs is based on a weighted average of each of the model
estimates using the probability that each of themodels is cor-
rect, conditional on the set of models under consideration
being exhaustive and including the true model. [The model
averagingmethod used here is based on that described in 12].
We let the “true”model be denoted by randomvariableA that
can take values from 1,...,nA, where nA is the number of can-
didatemodels under consideration. The probability that each
of models 1,...,nA is correct is defined by a probability weight,
W (a), derived from some model selection measure. Here we
base the model probability weights on the smoothed DIC cri-
terion and use a formula of the same form as that described
for the smoothed Bayesian information criterion (BIC) and
smoothed AIC [32] as follows:
DICa
exp12 .DIC,a

a'1
nA
exp12 .DIC,a'
where DIC,aDICamaxa'DICa' is used for reasons of numer-
cal stability [12]. WDIC(a) is the estimated probability weight
ssigned tomodel a. TheDIC statistic is a Bayesian extension to
heAIC andmay be used to compare the fit of the differentmod-
ls, either nested or non-nested [11]. It takes account of both the
otal deviance and thenumber of parameters in themodel. All of
he models described in Price et al. [8,9] together with the SAT9
odel are included in thecandidatemodel spaceandprobability
eights were calculated for all of them. Only models found to
ave a non-negligible (WDIC(a) 0.005) weight are averaged.
The model averaged posterior distribution is defined as a
ixture of the posterior distributions of the component mod-
ls. The mean and variance of the marginal model averaged
osterior distribution for each parameter of interest 	 given
he data Y are shown below [32]:
	
Y

a1
nA
WDICaY .E	
Y, a

Var	
Y

a1
nA
WDICaY . Var	
Y, a
 E	
Y, a
E
Y2
It is possible to average over any parameter or function of
parameters estimated within the MCMC simulation. In cost-
effectiveness analysis 	 will typically represent such quan-
ities as the treatment and threshold specific expected net wonetary benefit, or probability that a treatment is themost
ost-effective. However, any parameter can be averaged over,
ncluding thenumber ofweeks spent in the STWstate, thenum-
er of exacerbations, or the probability of absorption. Posterior
ummary statistics such as the Incremental cost-effectiveness
atio or EVPI cannot be averaged over directly.
Cost-effectiveness parameters
A 1-year time horizon is used with weekly cycles. The weekly
cost for a single individual using each of the four different
treatments, along with costs [33] and utilities [34] of spending
a week in each state together with their distributional as-
sumptions are shown in Table 2. Costs and utilities for the TF
state (including treatment costs for usual care) were deter-
mined probabilistically as described in [34]. For all analyses,
the trial data, which was collected over a 12-week follow-up,
are extrapolated to a 1-year period. All patients are assumed
to start in the STW state.
The formula for the net benefit function for persons receiv-
ing treatment k and the incremental net benefit for using each
treatment B-D compared to treatment A for a 52-week period
are shown below:
NBk .UkCk
INBkNBkNB1
where  represents the willingness-to-pay threshold, varied
n increments of £1,000 from £0 to £50,000 for a single qual-
ty-adjusted life year (QALY); Uk and Ck are, respectively, the
expected utility and cost for a person who is receiving treat-
ment k where:
Ck
h1
52

j1
4
h,k,j SCj
h1
52

j1
3
h,k,jTCk
Uk
h1
52

j1
4
h,k,j SUj
Here SCj and SUj are the costs and utilities of spending a
ingle week in state j, and TCk is the cost of receiving treat-
ent k for a single week. h,k,j is the proportion of persons
n treatment k in state j during week h, h  0,1,...,52. This is
alculated using one-step transition probabilities defined
or 1-week time periods that have been generated from the
stimated calibrated (see below) transition rates using Kol-
ogorov’s forward equations [30,31]:
h,k,j
i1
3
h1,k,i pk,i,j1 0,k,1 1,
where persons are all assumed to start in the STW state, and i
indexes over the states that a person can occupy at time h1
from which a transition to another state is possible.
The transition probabilities pk,i,j(1) for each treatment are
stimated by calibrating the estimated treatment effects
rom a mixed treatment comparison meta-analysis [25–27]
eported in Price et al. [8,9] to a common baseline. The base-
ine transitions rates in the A arm of the A versus D trial
ere chosen because this trial has the most data. This was
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effects of treatments B to D to the baseline parameters on
the log-rate scale. These calibrated transition rates are then
converted to transition probabilities for each of the treat-
ments using Kolmogorov’s forward equations as previously
described.
We average over the joint posterior distribution of Uk and
Ck to obtain E(NBk) and choose the treatment k* that maxi-
mises this. The probability that each of the treatments is the
most cost-effective for thresholds in increments of £1,000 be-
tween £0 and £50,000 is estimated by calculating the propor-
tion of MCMC sweeps in which the net benefit of using this
treatment is the highest [13,35].
EVPI
The EVPI for a singlemodel a is equal to the expectation of the
aximum net benefit minus the maximum of the expecta-
ions of the net benefits [36]:
VPIa EamaxkNBk, amaxkEa	NBk, a

where a is the vector of all of the parameters in model a.
The EVPI of the averaged model is calculated as follows.
There are nA possible models with parameter sets 1,....,nA,
nd the probability that model a is the “true” model (condi-
ional on one of the models being correct) is Pr(Aa)WDIC(a)
using DICweights formodel averaging. Then the expected net
benefit averages over candidatemodels aswell as over param-
eters a, so that based on current information, expected net
enefit under the optimal intervention k*, is given by:
nA
Table 2 – The parameter estimates and distributions used
the states for a single week. The exacerbation state implie
These represent primary care exacerbations (X1), exacerba
exacerbations requiring inpatient care (X3).
Parameter Distribution
Treatment cost (TCk)
A NA
B NA
C NA
D NA
Utility (SUj)
STW Beta
UTW Beta
X1 Beta
X2 Beta
X3 Beta
TF Beta
State cost (SCj)
STW Normal
UTW Normal
X1 Normal
X2 Normal
X3 Normal
TF Normal
Weight
X1 Beta
X2 NA 1 
X3 Beta (1 
SD, standard deviation; STW, Successfully Treated Week; UTW, UnsuaxkEA	Ea	NBk, a

maxk
a1
WDICaEa	NBk, a
Similarly, the expected net benefit under perfect information
is given by:
EA	Ea	maxkNBk, a


a1
nA
WDICaEa	maxkNBk, a

EVPI is therefore:
EVPIaverage
a1
nA
WDICaEa	maxkNBk, a

maxk
a1
nA
WDICaEa	NBk, a

Note that the EVPI of the averaged model is not the average of
the EVPIs under the component models because the maxi-
mum function is nonlinear.
Implementation
A Bayesian approach is taken to inference. Marginal posterior
distributions are generated for each of the cost-effectiveness
parameters using MCMC simulation inWinBUGS [37]. Embed-
dedwithin this simulation, theWBDiff [38] add-onwas used to
solve the series of Kolmogorov’s forward differential equa-
tions required to estimate the transition probabilities from the
transition rates using numerical integration techniques. A
burn-in period of 10,000 iterations was used for the MCMC
simulation and the statistics drawn from the marginal poste-
rior distributions of the parameters and other functions are
based on samples of 40,000 iterations. Estimates of EVPIaverage
were obtained by transporting the raw MCMC outputs for the
treatment-specific net benefit statistics calculated for each
cost-effectiveness threshold into Excel (Microsoft Corp.,
Redmond, WA) and sampling from them in proportions de-
nerate the costs Ck and utilities Uk for occupying each of
t one of three different levels of management is required.
s managed in the hospital emergency room (X2), and
n SD Source
NA Briggs
NA Briggs
NA Briggs
NA Briggs
9 0.0099 Price et al. 2002
1 0.081 Price et al. 2002
3 0.063 Price et al. 2002
6 0.026 Price et al. 2002
6 0.026 Price et al. 2002
9 NA Price et al. 2002
0 Price et al. 2002
0 Price et al. 2002
2 Hoskins et al. 1998
21 Hoskins et al. 1998
301 Hoskins et al. 1998
NA Hoskins et at. 1998
6 4.05 Trial data
X3 NA Hoskins et al. 1998
0.036 (1  X1) * 3.26 Hoskins et al. 1998
sfully Treated Week; X, Exacerbation; TF, Treatment Failure.to ge
s tha
tion
Mea
9
5
11
14
0.9
0.8
0.6
0.2
0.2
0.8
0
0
101
120
2047
14
0.8
X1 
X1) fined by the DIC weights using Monte Carlo simulation and
d0
212 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8are based on a sample of 500,000. The WinBUGS and WBDiff
code for the analysis are provided in the Appendix found at:
doi:10.1016/j.jval.2010.08.001.
Results
For the averaged model the estimated weights for each of the
treatment models are provided in Table 3. The HI model was
found to have a 94% probability of being correct, with the M&I
model having a 3% chance of being correct and the remaining
3% being distributed between the other models described
above. All of the remaining models described in Price et al.
[8,9] and the SAT9 model were found to have probabilities of
WDIC(a)  0.005 so were therefore not averaged over. Our can-
idate model space therefore consists of nA 5 models.
Treatment decision
Cost-effectiveness planes [39] showing the differences in the
expected costs and utilities generated fromeachmodel during
each realization of the MCMC simulation for the differences
between treatments A and D calculated using the within trial
pair-wise comparisons with the individual trial baselines are
shown in Figure 2. The greater variance in the distribution
under the saturatedmodels is evident. The distribution under
the one treatment parameter HI model is consistently nar-
rower than the other structured models, although the differ-
ences between them are small compared with the difference
between the structured and saturated models. The locations of
the distributions are approximately the same for allmodels. The
estimated expected net benefit associated with each treatment
for a cost-effectiveness threshold of £30,000 for each model is
shown in Table 3. The optimal treatment k* differs between
models. In the saturatedmodels, and I,P&Lmodel treatment B is
preferred, but in the remaining models, including the averaged
Table 3 – Key statistics estimated from each treatment mo
probabilities that each of the models (saturated nine-param
health improvement (HI) model, maintenance and improve
Improvement, prevention and longevity (I,P&L) model) are
(NB) and expected value of perfect information (EVPI) in po
the A vs. D study baseline for a threshold of £30,000 per qu
Statistic SAT9 SAT6
DIC 150 138
WDIC(a) 0 0.01
E(NBA) 25,270 25,280 2
E(NBB) 25,620 25,340 2
E(NBC) 25,210 25,010 2
E(NBD) 24,930 24,940 2
k* B B
EVPI 467 384
pD 58 53
Number of parameters 90 60
Probability cost-effective (A) 0.24 0.32
Probability cost-effective (B) 0.54 0.6
Probability cost-effective (C) 0.22 0.07
Probability cost-effective (D) 0.01 0.01model, treatment A is the most cost-effective.Decision uncertainty and EVPI
The probabilities that each of the four treatments is the most
cost-effective for incremental cost/QALY thresholds between
£0 and £50,000 are plotted on cost-effectiveness acceptability
curves [13] (Fig. 3). In the HI, M&I, I&P, and averaged models
there is threshold willingness-to-pay around £6000 per QALY,
abovewhich treatment A is themost likely treatment to be cost-
effective,with treatment B being themost likely to be cost-effec-
tive below this threshold. The results from the saturated and
I,P&L parameterizations are somewhat different with treatment
B having the highest probability of being the most effective, al-
though the superiority of B is highly uncertain.
The EVPI at different thresholds calculated for a decision
space including all four treatments is shown in Figure 4. As
would be expected from earlier results, the EVPI calculated
with the saturated models is uniformly much larger than that
calculated using the structured models. For thresholds above
£5000 per QALY gained the EVPI for the HI model is consis-
tently lower than all of the other models. For thresholds be-
tween £10,000 and £40,000 it is at least 300-fold and oftenmore
than 1,000-fold smaller than the EVPI estimated using the sat-
urated models. It is between about 10- and 100-fold smaller
than that calculated with the second best fitting (i.e., M&I)
model. The EVPI for the averaged model lies between the es-
timates for the HI, and M&I models although it is closer in
magnitude to the former. The estimates vary from being ap-
proximately the same at lower thresholds to up to a 30-fold
increase in the EVPI estimated from the averagedmodel. For a
threshold of £30,000/QALY the EVPI estimated from the aver-
agedmodel is £10 (Table 3), compared to £0.4 for the HImodel.
The results demonstrate that when a structured parameter-
ization representing the mechanism of action of the relative
treatment effects is used, rather than a saturated approach that
assumes the treatments act independently on each of the tran-
sitions, the decision uncertainty and EVPI are much lower. The
eviance information criterion (DIC) statistics and
r (SAT9) model, saturated six-parameter (SAT6) model,
t (M&I) model, improvement and prevention (I&P), and
ect based on the smoothed DIC. The expected net benefit
s associated with each treatment for persons calibrated to
-adjusted life year.
M&I I&P I,P&L Average
135 138 137 NA
.94 0.03 0.01 0.01 NA
25,290 25,240 25,270 25,242
25,090 24,850 25,610 24,880
24,890 24,860 24,970 24,816
24,930 24,940 24,950 24,959
A A B A
.4 34 5 88 10
40 40 44 NA
40 40 45 NA
.99 0.78 0.94 0.3 0.97
0.17 0.02 0.66 0.02
0.02 0.01 0.03 0
.01 0.24 0.03 0.01 0.01del: d
ete
men
corr
und
ality
HI
129
0
5,240
4,860
4,810
4,960
A
0
32
35
0
0
0estimates of the cost-effectiveness analysis parameters are
213V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8moreprecise.Cost-effectiveness results arevery similar in theHI
and averagedmodels. However, the EVPI is around 20- to 30-fold
higher for the averagedmodel for thresholds of between £20,000
and £30,000/QALY than for the HI model, suggesting that ac-
counting for structural uncertainty could have an important ef-
fect on decisions about future research.
Discussion
Fromadecision-makingperspective, the ideal approach tousing
Markov disease progression models to make treatment deci-
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Fig. 2 – Cost-effectiveness planes plotted for each treatmensions would have the following properties. First, it would bebased on statistical estimationmethods that can incorporate all
the available evidence on each of the available treatments [40].
Second, it should allow flexibility to explore and account for
which state transition or transitions are affected by treatment,
using standardmethods for model critique andmodel selection
[8,9]. Third, it should respect the randomisation structure in the
evidence, combining where necessary randomized evidence on
pair-wise comparisons to make inferences about relative effi-
cacy of several treatments [25,27]. Fourth, it should be able to
calibrate the absolute effects of treatment to conform with evi-
denceonacohortorother suitabledata source that is considered
relevant to the decision [10,13,41]. Finally, it is desirable that the
SAT6 model - CE plane A vs D
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del for the within study A versus D treatment comparison.t mostatistical approach to estimation is compatible with uncer-
214 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8Fig. 3 – Cost-effectiveness acceptability curves (CEACs) for the four treatments generated using saturated nine-parameter
(SAT9) model, saturated six-parameter (SAT6) model, health improvement (HI) model, maintenance and improvement
(M&I) model, improvement and prevention (I&P), and improvement, prevention, and longevity (I,P&L) model.
215V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8tainty propagation as understood in a decision context, of par-
ticular concern in nonlinear models such as here [8,9,42].
Although there are alternative approaches that meet some
of these criteria, previous work has shown that they are all
readily, and perhaps most conveniently [8–10], met by mod-
elling transition rates, rather than probabilities, within the
Bayesian MCMC framework offered by WinBUGS. Bayesian
MCMC not only facilitates simultaneous estimation of all of
the parameters, but its simulation framework readily allows
uncertainties in the joint posterior of the transition parame-
ters to be propagated into the cost-effectiveness analysis.
The research presented here demonstrates the dramatic
differences in the level of decision uncertainty between differ-
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Fig. 4 – Expected value of perfect information (EVPI) estimate
and £50,000.ent parameterizations for the treatment effect. Choice of pa-rameterization of the treatment effect is of primary impor-
tance for planning future research, but in this case it might
also affect the treatment decision. Use of the saturated mod-
els leads to the conclusion that treatment B is the most cost-
effective, whereas for most thresholds the structuredmodels,
with the exception of the I,P&Lmodel, show treatment A to be
the best. It is difficult to say how often a reversal of the deci-
sionwould occur in other Markovmodels because thismay be
a result of the assumptions about the cost and utility associ-
atedwith the TF state. Alternatively, the extreme sensitivity of
uncertainty measures to parameterization may be due to the
complex posterior correlations between treatment parame-
ters, inducedbyestimation fromacommondataset. Because the
shold 
mates for treatments A-D
HI
I&P
M&I 
I,P&L
(£'s)
each model for cost-effectiveness thresholds between £0hre
sti
d 
d bycentral estimates are nonlinear functions of the parameters, it
216 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 5 – 2 1 8might be expected that changes to these distributions, even
changes that just make them more diffuse, will result in differ-
ences in the central estimates of the decision parameters.
Uncertainty in the decision was generally observed to in-
crease with the number of treatment parameters (Fig. 2). One
possible reason for this is that the E(NMBk) statistics are de-
rived from differences in the distributions of the state occu-
pancy probabilities between the subjects receiving different
treatments, and these differences are completely defined by
the treatment effect parameters. If there are more parame-
ters, there is more scope for differences in these distributions.
However, the extent of the difference between the saturated
models, which (parameterized by the transition probabilities)
has represented the standard methodology, and the more
structured models is striking. Standard errors of incremental
net benefit were reduced up to eight- or ninefold, and the
expected loss attached to decision uncertainty by factors of
several hundreds.
In this example, EVPI is extremely high, and due to the high
prevalence of asthma would warrant further research what-
ever model is assumed. In other instances, this will not be the
case, and policy makers responsible for research decisions
may ask for a range of model structure scenarios that can be
considered to span from probably underestimating decision
uncertainty to probably overestimating it. In this instance, the
HI model had the lowest DIC of all the proposed treatment
structures. However, acceptance of this model underesti-
mates the decision uncertainty, as the evidence could not rule
out more complex models [8,9]. At the other extreme, the sta-
tistical evidence gave no justification for using a saturated
parameterization to model this dataset, and there were indi-
cators that the numbers of parameters in these models were
more than could be properly identified by the likelihood, and
that the saturated models, especially SAT9, seriously overfit
the data. This does not, in itself, indicate that the saturated
models are overparameterized, just that there is insufficient
data to inform them. Instead we would rely on the implausi-
bility of a model in which, for example, the treatment effects
operating on all the forward transitions are all completely un-
related. On this basis a research funder could safely regard the
EVPI calculated under the saturated model as highly exagger-
ated, and not even useful as an upper bound. The remaining
models produce estimates of the EVPI that lie somewhere be-
tween the two and may provide a reasonable compromise.
However, there is no sound basis to choose between them and
it is difficult to determine whether these models under- or
overestimates decision uncertainty.
Model averaging can be used to account for structural un-
certainty in the parameterization of themodel, allowing for an
accurate characterisation of decision uncertainty [20]. The
standard method for model averaging is to weight the models
by the true relative posterior probabilities that they are correct
[43]. This can be done using reversible jump MCMC simula-
tion. Although there is a reversible-jump add-on package for
WinBUGS, currently it can only be used to perform covariate
selection in normal linear and logistic regression models and
spline fitting with unknown numbers of knots, so it cannot
handlemodels of the type described here. An alternative, sim-
pler approach is to estimate the model weights usingsmoothed information criteria. Both the BIC [12,21,44], and the
AIC [12,21] are commonly used for model averaging for Bayes-
ian and classical models, respectively. The use of DIC is more
controversial, although the idea was suggested in the discus-
sion of the article by Speigelhalter et al. [11] and this has been
extended by Jackson et al. [22] to account for sampling uncer-
tainty arising from using data to assess future predictive abil-
ity, using Bayesian bootstrapping. Table 4 compares the esti-
mated model weights calculated using each of the smoothed
AIC, smoothed BIC, and smoothed DIC replacing DIC with AIC
or BIC as appropriate. It shows that the choice of method for
calculating the model weights can have a very large effect on
themodelweights. If the BIC is used then theHImodel is given
100% of the weight. There is no model uncertainty, and the
EVPI for the averaged model is equal to that of the HI model.
Use of the AIC leads to far more model uncertainty than the
DIC, and would lead to a far higher estimate of EVPI. These
results are in keeping with Jackson et al. [21] who found large
differences between model weights estimated using the BIC
and AIC. The BIC focuses the decision on identifying a correct
model whereas the DIC and AIC focus on identifying the
model with the best predictive ability. There is no clear guid-
ance on how to choose between the measures so analysts are
required to take a view. Here we have chosen to focus on
predictive ability, which seems sensible when comparing
medical models because it is unlikely that any of them will
represent the exact process of disease. Intuitively, it would
seem tomake sense to use the same tool formodel selection as
that to derive model-averaging weights, and this was our moti-
vation forusing theDICweightshere. TheDIC iswell established
as the model selection tool of choice in Bayesian analyses, al-
though its popularity is due in part to the ease inwhich it can be
calculated within MCMC sampling using software such as Win-
BUGS. However the use of the DIC inmodel averaging should be
limited to those situations where the use of the DIC itself is ap-
propriate. For example, DIC depends on the parameterization,
and on rough approximations, such as posterior normality,
which are not true for mixture models [11,45].
The question of which candidate models should be in-
cluded in the model space is difficult. To fully account for all
structural uncertaintywe should theoretically average over all
possible models. If we omit models with non-negligible
Table 4 – Model weights estimated using the smoothed
Bayesian information criterion (BIC), smoothed Akaike
information criterion (AIC), and smoothed deviance
information criterion (DIC).
Model BIC
weight
AIC
weight
DIC
weight
9 transition saturated (SAT9) 0.00 0.00 0.00
6 transition saturated (SAT6) 0.00 0.00 0.01
Health Improvement (H&I) 1.00 0.50 0.94
Maintenance & Improvement
(M&I)
0.00 0.31 0.03
Improvement & Prevention
(I&P)
0.00 0.12 0.01
Improvement, prevention &
longevity (I,P&L)
0.00 0.06 0.01weight then this could under or overestimate EVPI. However,
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impractical, and only a limited set of models are explored. For
examplewe initially consideredmodelswith between five and
nine transitions, but after a preliminary selection process
identified a six-transition model to be adequate [8]. We then
restricted exploration of treatment effects to six-transition
models only (although the saturated model SAT9 is included
as a candidate model). This kept the model space to a feasible
size. Nevertheless, structural uncertainty in the number of
transitions that should be included in the model was not ac-
counted for. Furthermore, there are other alternatives we
could have explored, such as hierarchical models for treat-
ment effects across different transitions. We advocate an ap-
proach of limiting candidate models to those that are clini-
cally plausible, and then use the Occam’swindowmethod [46]
f only averaging over models that have a non-negligible
eight (a probability P  0.005 of being correct was chosen to
ndicate a negligible weight). Clinical experts can provide
aluable input to help identify clinically plausiblemodels. The
nput from clinical experts could be taken a step further by
liciting formal priors about the plausibility of the different
odels. The Bayesian approach provides a flexible framework
n which such priors could be quantitatively incorporated into
he analysis. External data may also be of value. For example
erewe incorporateddata fromtwo trials comparing treatments
versus F and G versus H, which were external to the decision
trategy space, to inform the model selection process [8].
We found that the averaged model was dominated by the
I model, which was accorded a probability of 0.94 on the
moothed DIC criterion. Even in this case incorporating struc-
ural uncertainty has a very large influence on the EVPI in-
reasing it relative to the HI model by 20- to 30-fold over the
ange of cost-effectiveness thresholds commonly considered
o be appropriate for the United Kingdom. This is because
ven though there is little model uncertainty, the conse-
uences of using a different model are high. Our results are
onsistent with the findings of Bojke et al. [19] who found that
hen equal model weights were used the EVPI estimated us-
ng model averaging differed by a factor of up to 35 when
ompared to the lowest EVPI of the candidate models. How-
ver, in principle model averaging could reduce decision un-
ertainty and EVPI compared to the best fittingmodel if model
veraging were to push the incremental net benefit further
way from the decision threshold.
Themethodology presented can be readily extended to the
omputation of expected value of partial perfect information
nd expected value of sample information by adding an addi-
ional layer of expectation over candidate models, A, around
he expectation overmodel parameters, a, in the correspond-
ing formulae. However, we would expect this additional layer
of expectation to add to the computational burden of these
often computationally expensive calculations.
Conclusions
This article shows that alternative parameterizations of treat-
ment effects in Markov models of disease progression can
have an extreme affect on decision uncertainty and the ex-pected value of further research, and even on reimbursement
decisions. This structural uncertaintywas accounted for using
Bayesian model averaging and a formula for estimating the
EVPI within a model-averaging framework is introduced.
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